HeartWare stock rises in run-up to FDA panel vote despite concerns
This article was originally published in Clinica
Executive Summary
Thoratec's monopoly of the US heart assist market may be nearing an end as the HeartWare ventricular assist device (HVAD), the blood pump developed by Thoratec's closest rival HeartWare International, comes under review today by the FDA advisory panel.